1. Home
  2. EWTX vs ELME Comparison

EWTX vs ELME Comparison

Compare EWTX & ELME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EWTX
  • ELME
  • Stock Information
  • Founded
  • EWTX 2017
  • ELME 1960
  • Country
  • EWTX United States
  • ELME United States
  • Employees
  • EWTX N/A
  • ELME N/A
  • Industry
  • EWTX Biotechnology: Pharmaceutical Preparations
  • ELME Real Estate Investment Trusts
  • Sector
  • EWTX Health Care
  • ELME Real Estate
  • Exchange
  • EWTX Nasdaq
  • ELME Nasdaq
  • Market Cap
  • EWTX 1.6B
  • ELME 1.5B
  • IPO Year
  • EWTX 2021
  • ELME N/A
  • Fundamental
  • Price
  • EWTX $21.22
  • ELME $16.64
  • Analyst Decision
  • EWTX Buy
  • ELME Hold
  • Analyst Count
  • EWTX 10
  • ELME 5
  • Target Price
  • EWTX $36.90
  • ELME $15.00
  • AVG Volume (30 Days)
  • EWTX 1.0M
  • ELME 1.2M
  • Earning Date
  • EWTX 11-06-2025
  • ELME 10-23-2025
  • Dividend Yield
  • EWTX N/A
  • ELME 4.28%
  • EPS Growth
  • EWTX N/A
  • ELME N/A
  • EPS
  • EWTX N/A
  • ELME N/A
  • Revenue
  • EWTX N/A
  • ELME $246,959,000.00
  • Revenue This Year
  • EWTX N/A
  • ELME N/A
  • Revenue Next Year
  • EWTX N/A
  • ELME N/A
  • P/E Ratio
  • EWTX N/A
  • ELME N/A
  • Revenue Growth
  • EWTX N/A
  • ELME 3.10
  • 52 Week Low
  • EWTX $10.60
  • ELME $13.95
  • 52 Week High
  • EWTX $35.99
  • ELME $18.08
  • Technical
  • Relative Strength Index (RSI)
  • EWTX 74.48
  • ELME 47.29
  • Support Level
  • EWTX $16.70
  • ELME $16.33
  • Resistance Level
  • EWTX $18.26
  • ELME $16.88
  • Average True Range (ATR)
  • EWTX 1.25
  • ELME 0.18
  • MACD
  • EWTX 0.39
  • ELME 0.02
  • Stochastic Oscillator
  • EWTX 93.28
  • ELME 48.69

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

About ELME Elme Communities

Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.

Share on Social Networks: